MK0524A Phase IIb Study
Part A: This study will determine that MK0524 is well tolerated and does not effect lipids and blood glucose when given alone.
Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids and blood glucose.
Drug: Comparator: niacin / Duration of Treatment: 17 Weeks
Drug: MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks
Drug: Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on Niacin-Induced Flushing in Lipid Clinic Patients|
- To determine the effect of MK0524A on lipids and blood glucose [ Time Frame: 17 Weeks ]
- To establish the dose for limiting flushing symptoms induced by NIASPAN (R) [ Time Frame: 17 Weeks ]
|Study Start Date:||June 2004|
|Study Completion Date:||June 2004|